Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 282.8 Million EUR | -34.4% |
| 2022 | 489.3 Million USD | 53.18% |
| 2021 | 289.1 Million EUR | -22.41% |
| 2020 | 335.7 Million EUR | 20.03% |
| 2019 | 309.2 Million EUR | 18.25% |
| 2018 | 294.6 Million EUR | -9.07% |
| 2017 | 324.5 Million EUR | -3.8% |
| 2016 | 356.1 Million EUR | -0.1% |
| 2015 | 309.3 Million EUR | 6.2% |
| 2014 | 312.9 Million EUR | 2.19% |
| 2013 | 305.6 Million EUR | -4.11% |
| 2012 | 319.2 Million EUR | -2.33% |
| 2011 | 326.6 Million EUR | 9.72% |
| 2010 | 297.4 Million EUR | 20.65% |
| 2009 | 246.5 Million EUR | 9.9% |
| 2008 | 224.3 Million EUR | -0.8% |
| 2007 | 226.1 Million EUR | 109.16% |
| 2006 | 108.1 Million EUR | -52.13% |
| 2005 | 231.6 Million EUR | 18.84% |
| 2004 | 191.1 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 73.04 Million EUR | -35.44% |
| 2024 Q2 | 65.8 Million EUR | 14.74% |
| 2024 Q3 | 202 Million EUR | 157.0% |
| 2023 Q1 | 72.72 Million USD | 30.93% |
| 2023 FY | - EUR | -34.4% |
| 2023 Q4 | 77.48 Million EUR | -21.52% |
| 2023 Q3 | 98.73 Million USD | 67.63% |
| 2023 Q2 | 58.89 Million USD | -19.01% |
| 2022 Q3 | 250.1 Million EUR | 159.97% |
| 2022 FY | - USD | 53.18% |
| 2022 Q2 | 96.2 Million EUR | 16.47% |
| 2022 Q4 | 55.54 Million USD | -77.79% |
| 2022 Q1 | 82.6 Million EUR | 58.24% |
| 2021 Q4 | 52.2 Million EUR | -23.01% |
| 2021 Q1 | 100.25 Million EUR | 201.06% |
| 2021 Q2 | 91.67 Million EUR | -8.56% |
| 2021 Q3 | 67.8 Million EUR | -26.04% |
| 2021 FY | - EUR | -22.41% |
| 2020 Q3 | 65.2 Million EUR | -32.44% |
| 2020 Q1 | 84.4 Million EUR | 53.18% |
| 2020 Q2 | 96.5 Million EUR | 14.34% |
| 2020 FY | - EUR | 20.03% |
| 2020 Q4 | 33.3 Million EUR | -48.93% |
| 2019 Q2 | 52.2 Million EUR | -5.26% |
| 2019 Q1 | 55.1 Million EUR | -20.03% |
| 2019 FY | - EUR | 18.25% |
| 2019 Q4 | 55.1 Million EUR | -39.45% |
| 2019 Q3 | 91 Million EUR | 74.33% |
| 2018 FY | - EUR | -9.07% |
| 2018 Q4 | 68.9 Million EUR | 53.79% |
| 2018 Q3 | 44.8 Million EUR | -35.72% |
| 2018 Q2 | 69.7 Million EUR | -0.29% |
| 2018 Q1 | 69.9 Million EUR | -5.16% |
| 2017 Q4 | 73.7 Million EUR | 34.0% |
| 2017 Q3 | 55 Million EUR | -22.1% |
| 2017 Q2 | 70.6 Million EUR | -20.05% |
| 2017 Q1 | 88.3 Million EUR | 49.92% |
| 2017 FY | - EUR | -3.8% |
| 2016 Q3 | 92.2 Million EUR | 10.02% |
| 2016 Q4 | 58.9 Million EUR | -36.12% |
| 2016 Q1 | 80.9 Million EUR | 58.32% |
| 2016 Q2 | 83.8 Million EUR | 3.58% |
| 2016 FY | - EUR | -0.1% |
| 2015 Q3 | 58.6 Million EUR | -21.13% |
| 2015 FY | - EUR | 6.2% |
| 2015 Q4 | 51.1 Million EUR | -12.8% |
| 2015 Q2 | 74.3 Million EUR | -11.65% |
| 2015 Q1 | 84.1 Million EUR | 62.98% |
| 2014 Q3 | 64.2 Million EUR | -25.61% |
| 2014 Q1 | 68 Million EUR | 8.8% |
| 2014 Q4 | 51.6 Million EUR | -19.63% |
| 2014 FY | - EUR | 2.19% |
| 2014 Q2 | 86.3 Million EUR | 26.91% |
| 2013 Q1 | 76.1 Million EUR | 37.12% |
| 2013 FY | - EUR | -4.11% |
| 2013 Q2 | 62.3 Million EUR | -18.13% |
| 2013 Q4 | 62.5 Million EUR | -6.99% |
| 2013 Q3 | 67.2 Million EUR | 7.87% |
| 2012 FY | - EUR | -2.33% |
| 2012 Q1 | 79.8 Million EUR | 29.76% |
| 2012 Q4 | 55.5 Million EUR | -27.92% |
| 2012 Q3 | 77 Million EUR | 13.91% |
| 2012 Q2 | 67.6 Million EUR | -15.29% |
| 2011 Q1 | 94.2 Million EUR | 76.07% |
| 2011 Q3 | 66 Million EUR | -0.6% |
| 2011 Q4 | 61.5 Million EUR | -6.82% |
| 2011 FY | - EUR | 9.72% |
| 2011 Q2 | 66.4 Million EUR | -29.51% |
| 2010 Q3 | 71.3 Million EUR | 15.75% |
| 2010 Q4 | 53.5 Million EUR | -24.96% |
| 2010 Q1 | 72 Million EUR | 61.07% |
| 2010 FY | - EUR | 20.65% |
| 2010 Q2 | 61.6 Million EUR | -14.44% |
| 2009 Q2 | 51.4 Million EUR | -12.88% |
| 2009 FY | - EUR | 9.9% |
| 2009 Q4 | 44.7 Million EUR | -21.3% |
| 2009 Q3 | 56.8 Million EUR | 10.51% |
| 2009 Q1 | 59 Million EUR | 0.0% |
| 2008 FY | - EUR | -0.8% |
| 2007 FY | - EUR | 109.16% |
| 2006 FY | - EUR | -52.13% |
| 2005 FY | - EUR | 18.84% |
| 2004 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AstraZeneca PLC | 13.28 Billion USD | 97.872% |
| Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 98.544% |
| CSPC Pharmaceutical Group Limited | 1.14 Billion USD | 75.367% |
| Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 812.253% |
| Novartis AG | 19.51 Billion USD | 98.551% |
| PT Kalbe Farma Tbk. | 288.13 Million USD | 1.851% |